Anne M. Tierens

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications

Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8.

Mutational Landscape and Clinical Outcomes in AML With Sole Trisomy 8.

Journal: Hematological oncology
Published: March 12, 2026

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Journal: Trials
Published: February 13, 2026

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse.

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse.

Journal: Pediatric blood & cancer
Published: December 10, 2025

Don't fly and freeze: impact of ex vivo time, cell density and cryopreservation on allogeneic stem cell grafts.

Don't fly and freeze: impact of ex vivo time, cell density and cryopreservation on allogeneic stem cell grafts.

Journal: Cytotherapy
Published: May 25, 2025

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Journal: Blood
Published: March 31, 2025

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel.

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel.

Journal: Blood
Published: March 31, 2025

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.

Journal: Haematologica
Published: March 07, 2025

An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.

An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.

Journal: Science translational medicine
Published: January 01, 2025

Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.

Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 11, 2024

Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia.

Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia.

Journal: Cancers
Published: March 14, 2024

Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 protocol.

Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 protocol.

Journal: Haematologica
Published: February 17, 2024

A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.

A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.

Journal: Blood advances
Published: October 06, 2023
Showing 1-12 of 75

Last Updated: 09/26/2026